Sheldon is an accomplished leader in the cardiovascular space and brings over 25 years of leadership roles to Esperion. Most recently, he was with chief commercial officer at Portola pharmaceuticals until it was acquired by Alexion. Prior to joining Portola, Sheldon was senior vice president and head of the cardiovascular franchise for Sanofi where he led U.S. business operations and product launches in more than 20 countries. Previously, he served as vice president and global brand leader for the cardiovascular division of Merck & Co, Inc. where, for more than 25 years, he took on roles of increasing responsibility within the Company’s cardiovascular and thrombosis franchises and led marketing for the launch of ezetimibe.
Sheldon holds a Master of Business Administration from Monmouth University, and a Bachelor of Applied Science from Drexel University. He also completed the leadership program at The Wharton School.
Jeffrey Berkowitz was appointed to our board of directors in November 2017.
Jeffrey is the President and CEO of Real Endpoints.
Previously, he was the Executive Vice President of Optum, Inc., a health services platform business of UnitedHealth Group, Inc. Prior he was Executive Vice President and President of Pharma and Global Market Access with Walgreens Boots Alliance, Inc., a global pharmacy-led health and well-being enterprise, where he was responsible for generic and branded procurement, specialty pharmacy, inventory management, and overseeing relationships with pharmaceutical companies as well as pricing and reimbursement strategies with all payer segments.
Additional experience includes serving as president of Walgreens Boots Alliance Development, GmbH, a joint venture between Walgreens Co. and Alliance Boots located in Switzerland; and having held a variety of senior executive positions with increasing responsibility in market access, sales, and marketing with Merck and Schering-Plough, as well as serving as a healthcare attorney with Proskauer, LLP.
Jeffrey earned his BA in political science from Union College in Schenectady, NY, and his JD from Brooklyn Law School in Brooklyn, NY.
Alan Fuhrman was appointed to our board of directors in March 2020.
Alan is a member of the board of directors for SpringWorks Therapeutics and Checkmate Pharmaceuticals.
Previously, Alan served on the board of directors and as Chair of the Audit Committee for Loxo Oncology until its sale to Eli Lilly in the first quarter of 2019. He previously served as the Chief Financial Officer of Amplyx Pharmaceuticals, Inc. from December 2017 through June 2020.
Prior to joining Amplyx, he served as CFO of Mirna Therapeutics, a publicly traded, clinical-stage microRNA company that merged with Synlogic in August 2017. Alan previously served as CFO of Ambit Biosciences, where he helped lead the company through its initial public offering and oversaw financial, investor, and administrative operations until its sale to Daiichi Sankyo in 2014. Earlier in his career, Alan practiced as a certified public accountant with Coopers & Lybrand.
Alan received a BS in both Business Administration and Agricultural Economics from Montana State University.
Antonio M. Gotto, Jr. was appointed to our board of directors in January 2014.
Dr. Gotto is Dean Emeritus at Weill Cornell Medicine, and Provost for Medical Affairs Emeritus for Cornell University.
From January 1997 to December 2011, he served as the Stephen and Suzanne Weiss Dean of the Joan and Sanford I. Weill Medical College of Cornell University and Provost for Medical Affairs of Cornell University.
Previously, Antonio served as J.S. Abercrombie Chair of Atherosclerosis and Lipoprotein Research and Chairman and Professor of the Department of Medicine at Baylor College of Medicine and Methodist Hospital.
Antonio currently serves as a member of the Institute of Medicine of the National Academy of Sciences and a Fellow of the American Academy of Arts and Sciences.
He is also a past president of the International Atherosclerosis Society and a past president of the American Heart Association. He is the current president of the National Lipid Association.
He was a member of the board of directors of Aegerion Pharmaceuticals, Inc. until December 2, 2016, when it merged to form Novelion Therapeutics, Inc. (NASDAQ: NVLN).
Antonio holds a BA degree from Vanderbilt University, a DPhil degree in Biochemistry from Oxford University in England, where he was a Rhodes Scholar, and an MD from Vanderbilt University School of Medicine.
Antonio completed his residency training at Massachusetts General Hospital in Boston, Massachusetts. He was the Chair of Medicine for 20 years at Baylor University Medical Center and Houston Methodist Hospital.
Dan Janney has served as a member of our board of directors since November 2012.
Dan is the Managing Partner of Alta Partners. He joined Alta at its founding and is a Managing Director.
He has over 20 years of successful early stage investing experience in life sciences. Dan’s focus on working with talented entrepreneurs to create companies around novel insights in biology and new approaches to drug discovery has led to the funding and development of 34 companies. Prior to Alta, Dan was a senior investment banker at Montgomery Securities where he advised life science companies on over $8 billion of equity and merger transactions.
Dan is currently on the board of directors of several public and private companies, including Allakos (NASDAQ:ALLK), Curasen Therapeutics, ESPERION Therapeutics (NASDAQ:ESPR), Evolve Biosystems, Krystal Biotech (NASDAQ:KYRS), Lassen Therapeutics, Prolacta Bioscience, and Viveve (NASDAQ:VIVE). In addition, he led Alta’s investments in Astex Pharmaceuticals (acquired by Supergen), Cellective (acquired by Medimmune), ChemGenex (ASX:CXS acquired by Cephalon), CoTherix (NASDAQ:CTRX acquired by Actellion), Definity Health (acquired by United Health), Dynavax (NASDAQ:DVAX), Endonetics (acquired by Medtronic), Ilex Oncology (NASDAQ:ILXO acquired by Millennium Pharmaceuticals), InterMune (NASDAQ:ITMN acquired by Roche), LJL Biosystems (NASDAQ:LJLB acquired by Molecular Devices), Mako Surgical (NASDAQ:MAKO acquired by Stryker) and Triangle Pharmaceuticals (NASDAQ:VIRS acquired by Gilead).
In 2006 and 2007, Dan was listed in Forbes’ Midas 100 List of Top Tech Investors. He is a member of The President’s Council of the J. David Gladstone Institutes, the Board of Directors of the California Academy of Sciences and serves on the Board of Regents of Georgetown University. He holds a B.A. from Georgetown University and a Master of Business Administration from the Anderson School at the University of California, Los Angeles.
Mark E. McGovern was appointed to our board of directors in February 2014.
Mark is a board-certified cardiologist with over 20 years of experience developing lipid regulating therapies.
His experience includes 11 years at Bristol-Myers Squibb, where Mark was responsible for the clinical development of Pravachol® (pravastatin sodium), in particular the programs for atherosclerosis regression and coronary heart disease prevention, including the WOSCOPS (West of Scotland Coronary Prevention Study), CARE (Cholesterol and Recurrent Events), and LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease) trials.
He subsequently spent 10 years at Kos Pharmaceuticals, where he last served as Executive Vice President, Medical Affairs, and Chief Medical Officer.
During his career at Kos, Mark oversaw the phase IV trials of Niaspan® (niacin extended-release) and the registration programs for the first combination lipid therapies, Advicor® (niacin extended-release/lovastatin) and Simcor® (niacin extended-release/simvastatin).
He currently serves as a consultant to the pharmaceutical industry for cardiovascular and atherosclerosis drug development.
Mark earned his bachelor’s degree summa cum laude from Princeton University and his medical degree from the University of Vermont. Mark is a Fellow of the American College of Cardiology and the American College of Physicians.
He has published extensively on lipid management and its role in the treatment of coronary heart disease.
Jay Shepard joined the board in May 2018.
Jay has served as the President and Chief Executive Office of Aravive (formerly Versartis), since May 2015 and has also served as Executive Chairman of the Board since early 2014.
He previously served as Executive Partner at Sofinnova Ventures, President and CEO of NextWave Pharmaceuticals (acquired by Pfizer), President and CEO of Ilypsa (acquired by Amgen), interim President and CEO of Relypsa (Ilypsa’s spin-out company, which was acquired by Galencia), and Vice President of Commercial Operations at Telik and Alza Pharmaceuticals (acquired by Johnson & Johnson).
Jay has over 30 years’ experience in the pharmaceutical, biotechnology, and drug delivery arenas and has participated in or led over 16 product launches by preparing markets and establishing sales and marketing operations.
He is a board member of Versartis, Inc., the Christopher & Dana Reeve Foundation, and the Santa Clara University Entrepreneurial School.
Jay holds a BS in business administration from the University of Arizona.
Nicole Vitullo has served as a member of our board of directors since April 2008.
Nicole joined Domain Associates, LLC, in 1999 and became a Partner in 2004.
With extensive experience in both public and private investing, Nicole’s current board memberships include Antios Therapeutics, ESPERION Therapeutics, Exalys Therapeutics, and Marinus Pharmaceuticals. Additionally, she was a former board observer at Iterum Therapeutics. Past board memberships include Achillion Pharmaceuticals (sold to Alexion), Calixa Therapeutics (sold to Cubist Pharmaceuticals), Celator Pharmaceuticals (sold to Jazz Pharmaceuticals), Cerexa (sold to Forest Laboratories), Durata Therapeutics (sold to Actavis), Onyx Pharmaceuticals, and VentiRx Pharmaceuticals (sold to Celgene).
In addition to investment responsibilities, Nicole is involved with the liquidation and distribution strategies for the public companies in Domain’s venture capital portfolios. For more than a decade, Nicole was responsible for Domain Public Equity Partners L.P., a fund focused on private investments in public companies.
Previous to Domain, Nicole was Senior Vice President at Rothschild Asset Management, Inc., where she had responsibility for the US public market investments of International Biotechnology Trust plc and Biotechnology Investments Limited.
Previous to Rothschild, Nicole served as the Director of Corporate Communications and Investor Relations at Cephalon, a publicly traded biotechnology company. Prior to Cephalon, Nicole spent 12 years at Eastman Kodak, where she held a number of positions including corporate development, where she was involved in the development and management of Kodak’s venture capital activities. She received her BA in Mathematics and her MBA in Finance from the University of Rochester.
Tracy Woody joined the board in June 2019. Tracy currently leads TMW Consulting where she works with both early-stage companies to provide initial commercial input, and companies in Phase 3 to develop and guide successful launch plans. Tracy previously served as Chief Commercial Officer of Versartis, Inc. and KemPharm, Inc.
Prior to KemPharm, Tracy was Vice President of Sales and Marketing of NextWave Pharmaceuticals (acquired by Pfizer), and Vice President of Business Development and Vice President of Sales and Marketing at Greer Laboratories. Tracy has over 20 years of commercial experience in pharmaceuticals, biologics, and medical devices, across a wide range of therapeutic areas in diverse markets. Tracy also has experience with multi-billion dollar revenue brands as well as products in the rare disease space.
Tracy holds a BS in Health Promotion and Applied Physiology from East Carolina University.